Skip to content

Rapid Detection of Pseudomonas Aeruginosa in Bronchoalveolar Lavage Fluid Using Label-free Single-particle Imaging Technology and Assessment of Post-treatment Efficacy in Patients With Pseudomonas Aeruginosa Infection

Rapid Detection of Pseudomonas Aeruginosa in Bronchoalveolar Lavage Fluid Using Label-free Single-particle Imaging Technology and Assessment of Post-treatment Efficacy in Patients With Pseudomonas Aeruginosa Infection

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06986512
Enrollment
100
Registered
2025-05-23
Start date
2025-09-01
Completion date
2025-11-30
Last updated
2025-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pseudomonas Aeruginosa Infection, Rapid Detection

Brief summary

The aim of this study is to observe specimens of bronchoalveolar lavage fluid from patients using a reflection enhanced dark-field scattering microscopy. By observing parameters such as the size, morphology, scattering intensity, and movement speed of pathogens, combined with the clinical characteristics of patients, a rapid diagnosis of Pseudomonas aeruginosa infection can be made. At the same time, the bronchoalveolar lavage fluid samples of patients infected with Pseudomonas aeruginosa before and after treatment were compared, and the quantity and vitality of Pseudomonas aeruginosa were observed to judge the efficacy of antibiotics.

Interventions

PROCEDUREbronchoscopy

We will perform bronchoscopy and collect bronchoalveolar lavage fluid (BALF)

Sponsors

The First Affiliated Hospital with Nanjing Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Aged 18 years and above * After admission, Pseudomonas aeruginosa was cultured in bronchoalveolar lavage fluid or lower respiratory tract aspirates

Exclusion criteria

* Age under 18 years old or over 90 years old * Pregnancy, lactation period -

Design outcomes

Primary

MeasureTime frameDescription
The size of pathogensFrom enrollment to the end of treatment at 2 weeksMeasure the size of pathogens
scattering intensity of pathogenFrom enrollment to the end of treatment at 2 weeksDetermine the shape of pathogens through scattering intensity
movement speed of pathogensFrom enrollment to the end of treatment at 2 weeksMeasure the movement speed of pathogens, such as flagellates like Pseudomonas aeruginosa, which have a fast movement speed

Countries

China

Contacts

Primary ContactWenkui Sun, Dr
sunwenkui@njmu.edu.cn+86 13914742215

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026